B-cell chronic lymphocytic leukemia (CLL) is the most common form of leukemia accounting for around 30% of all cases.
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Inherited predisposition to CLL is now well recognized, with epidemiological studies showing 3-to 7-fold elevations of risk in first-degree relatives of CLL cases. 1 Part of this genetic risk is likely to be explained by combinations of common, lowerpenetrance variants, making association studies an attractive means of identifying susceptibility alleles for CLL.
Recent studies have independently identified polymorphisms in the 8q24 region, including the single nucleotide polymorphism (rs6983267) to be strongly associated with risk of prostate [2] [3] [4] and colorectal cancer, 5 raising the possibility that 8q24 variants act as generic susceptibility alleles for neoplasia.
To explore the relationship between polymorphic variation at 8q24 and risk of CLL, we compared the frequency of rs6983267 genotypes in 984 cases and 4831 healthy controls. We included a high proportion of familial cases in the study as this enriches for an inherited genetic risk thereby increasing the probability of detecting an association. 6 Nine hundred and eighty-four patients with adult CLL (666 men and 318 women; mean age at diagnosis 61 years) ascertained through the Royal Marsden Hospital NHS Trust were included in the study. One hundred and thirty-three of the cases had one or more first-degree relatives affected with CLL. The diagnosis of B-cell CLL in cases was established using standard clinico-pathological and immunological criteria in accordance with current World Health Organization classification guidelines. 7 Control genotypes were based on previously published data we generated on 4831 healthy individuals (mean age 58 years; range 51-70; s.d.75). 5 All cases and controls were British Caucasians, and there were no obvious differences in the demography of cases and controls in terms of place of residence within the United Kingdom. Germline DNA from CLL patients was obtained from mouthwashes by using QIAamp DNA mini columns (Qiagen, Crawley, UK) and by following the manufacturer's protocol and quantified using PicoGreen (Invitrogen, Paisley, UK). The study was carried out with informed consent and ethical review board approval in accordance with the tenets of the Declaration of Helsinki Principles. Genotyping was performed by Kaspar (http://www.kbioscience. co.uk/chemistry/kaspar_chemistry-intro.htm), an allele specific PCR methodology implemented on an ABI7900HT platform (Applied Biosystems, Foster City, CA, USA). We confirmed 96 genotyping results at this single nucleotide polymorphism (SNP) by direct sequencing of 192 samples and obtained perfect concordance, thereby excluding technical artifact influencing findings. PCR primer sequences and amplification conditions are available upon request.
Genotypic frequencies in controls were tested for departure from Hardy-Weinberg equilibrium (HWE) using a w 2 test. The difference between allelic frequencies in cases and controls was calculated using the w 2 test. The risks associated with each SNP were estimated by odds ratios (ORs) using unconditional logistic regression, and associated 95% confidence intervals (CIs) calculated. All computations were undertaken using the statistical software package STATA (Version 8.2, Stata Corporation). A P-value of o0.05 was considered statistically significant in all analyses.
Genotypes for this SNP were successfully generated for all cases. The observed genotype frequencies were in accordance with HWE, providing no evidence of population stratification within the data set. Based on the number of cases and controls analyzed, and the population frequencies of alleles, our study has 80% power to demonstrate an OR of 1.2 associated with rs6983267 stipulating a P-value of 0.05.
Genotype frequencies of rs6983267 were not significantly different between cases (GG, n ¼ 263 (26.7%); GT ¼ 490 (49.8%); TT ¼ 231 (23.5%)) and controls (GG ¼ 1303 (27.0%); GT ¼ 2406 (49.8%); TT ¼ 1122 (23.2%)). There was therefore no evidence for an association between rs6983267 genotype and CLL; P ¼ 0.84 (allelic test) with ORs of 1.01 (95% CI: 0.86-1.19) and 1.02 (95% CI: 0.84-1.23) for heterozygotes and TT homozygotes, respectively. Adjustment for age and sex did not have an impact on study findings (data not shown).
On the basis of our data, there seems little evidence to support the tenet that variation at 8q24 significantly contributes to an inherited genetic susceptibility to CLL. While the underlying basis of an association of 8q24 variation and cancer risk is at present undefined, our data and the recent observation that variation at 8q24 is not associated with breast cancer risk 8 imply that spectrum of tumor risk conferred by this locus may be restricted to certain histologies. 
